PHERGain was a strategy-based study with a unique design. Previous trials of de-escalation strategies in HER2-positive, early-stage breast cancer have highlighted the importance of establishing innovative clinical designs, together with optimal selection of treatment and study population. WebThe definitive assessment of pathological complete response was done at this primary analysis; follow-up to assess invasive disease-free survival is continuing, hence these …

40% of patients with HER-2 positive breast cancer could do …

WebPHERGain was designed to see if imaging with positive emission tomography, also called a PET scan, could help find people with early-stage, HER2-positive breast cancer that … Web15. feb 2024 · PHERGain-2 study is an additional step forward and aims to assess the feasibility of chemotherapy de-escalation with neoadjuvant HP followed by adjuvant HP or T-DM1 using a pathological response-adapted strategy in low-risk HER2-positive early breast cancer pts. Trial Design: PHERGain-2 is a multicenter, open-label, non-comparative, phase … birdhouse design ideas

Chemotherapy de-escalation using an - The Lancet …

Web3. máj 2024 · PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy (CT) de-escalation in HER2-positive, stage I-IIIA, invasive, … Web19. máj 2024 · The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary … WebThe aim of CompassHER2-pCR study is to evaluate the de-escalation of chemotherapy for HER2 positive breast cancer after neoadjuvant chemotherapy and targeted therapy. 4 The PHERGain study will assess the effects of neoadjuvant treatment with dual target therapy (± endocrine therapy according to hormone receptor status) in patients with HER2 … bird house designs homemade